Risk factor
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT
Target Price
The average target price of 005500.KS is 24000 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell